Results 271 to 280 of about 44,894 (310)

Inhibition of CYP2D6 Activity by Bupropion

Journal of Clinical Psychopharmacology, 2005
The purpose of this study was to assess the effect of bupropion on cytochrome P450 2D6 (CYP2D6) activity. Twenty-one subjects completed this repeated-measures study in which dextromethorphan (30-mg oral dose) was administered to smokers at baseline and after 17 days of treatment with either bupropion sustained-release (150 mg twice daily) or matching ...
Michael, Kotlyar, Lisa H, Brauer, Timothy S, Tracy, Dorothy K, Hatsukami, Jennifer, Harris, Carrie A, Bronars, David E, Adson   +6 more
openaire   +2 more sources

Implementation of CYP2D6 genotyping in psychiatry

Expert Opinion on Drug Metabolism & Toxicology, 2009
Response to pharmacotherapy is subject to large inter-individual variation. Most medicine is metabolised by CYP450 enzymes, including CYP2D6. CYP2D6 activity is determined substantially by the genetic composition. Polymorphisms of CYP2D6 are associated with inadequate response on treatment with psychotropics. The large number of polymorphisms of CYP2D6
Harriët M, Loovers, Jan, van der Weide
openaire   +2 more sources

Influence of donor and recipient genotypes on CYP2D6 phenotype after liver transplantation: a study of mutations CYP2D6*3 and CYP2D6*4

European Journal of Clinical Pharmacology, 1998
After liver transplantation (LT), genotypic differences between the recipient and the transplanted liver, medications and post-LT complications may all affect drug metabolism. We have studied the effect of two CYP2D6 mutations in the donor and the recipient on post-LT CYP2D6 phenotype.The CYP2D6 phenotype was assessed in 48 patients before and after LT
O, Monek, G, Paintaud, Y, Bechtel, J P, Miguet, G, Mantion, P R, Bechtel   +5 more
openaire   +2 more sources

Recent examples on the clinical relevance of the CYP2D6 polymorphism and endogenous functionality of CYP2D6

dmdi, 2013
Abstract The cytochrome P450 2D6 (CYP2D6) belongs to a group of CYPs considered of utmost importance in the metabolism of xenobiotics. Despite being of only minor abundance in the liver, it is involved in the clearance of >25% of marketed drugs.
openaire   +2 more sources

Nomenclature for human CYP2D6 alleles

Pharmacogenetics, 1996
To standardize CYP2D6 allele nomenclature, and to conform with international human gene nomenclature guidelines, an alternative to the current arbitrary system is described. Based on recommendations for human genome nomenclature, we propose that alleles be designated by CYP2D6 followed by an asterisk and a combination of roman letters and arabic ...
Daly, A. K., Brockmöller, J., Broly, F., Eichelbaum, M., Evans, W. E., Gonzalez, F. J., Huang, J. D., Idle, J. R., Ingelman-Sundberg, M., Ishizaki, T., Jacqz-Aigrain, E., Meyer, U. A., Nebert, D. W., Steen, V. M., Wolf, C. R., Zanger, U. M.   +15 more
openaire   +3 more sources

Genetic Polymorphism in Cytochrome P450 2D6 (CYP2D6): Population Distribution of CYP2D6 Activity

Journal of Toxicology and Environmental Health, Part B, 2009
Cytochrome P-450 2D6 (CYP2D6) is involved in the metabolism of many therapeutic drugs even though the enzyme represents a small proportion of the total CYP content of human liver. In vivo phenotyping with probe drug substrates such as debrisoquine and dextromethorphan showed a clear separation between poor metabolizers (PM) and extensive metabolizers ...
Patricia, Neafsey, Gary, Ginsberg, Dale, Hattis, Babasaheb, Sonawane   +3 more
openaire   +2 more sources

MDMA (ecstasy) pharmacokinetics in a CYP2D6 poor metaboliser and in nine CYP2D6 extensive metabolisers

European Journal of Clinical Pharmacology, 2005
(CYP)isoform 2D6 [2]. HHMA is further metabolised to 4-hydroxy, 3-methoxymethamphetamine (HMMA) bycatechol- O-methyltransferase (COMT). HMMA in-duces vasopressin secretion to a higher extent thanMDMA and has been postulated to contribute to hyp-onatraemia observed in some MDMA acute intoxica-tions [4].
Rafael, de la Torre, Magí, Farré, Brian O, Mathúna, Pere N, Roset, Neus, Pizarro, Mireia, Segura, Marta, Torrens, Jordi, Ortuño, Mitona, Pujadas, Jordi, Camí   +9 more
openaire   +2 more sources

Genetic testing for CYP2D6 and CYP2C19 suggests improved outcome for antidepressant and antipsychotic medication.

Psychiatry Research, 2019
Individuals carrying genetic variants that result in non-extensive CYP2D6 and CYP2C19 enzyme activity seem to be more prone to non-response and side-effects of psychotropic medications.
Lucas M. Walden, E. Brandl, A. Tiwari, Sheraz Y. Cheema, N. Freeman, Nicole Braganza, J. Kennedy, Daniel J. Müller   +7 more
semanticscholar   +1 more source

CYP2D6 Genotype and Adjuvant Tamoxifen

Clinical Pharmacology & Therapeutics, 2014
A study by Province et al. for the International Tamoxifen Pharmacogenomics Consortium (ITPC) appeared in a recent issue of this journal.1 In addition to discussing this study and biomarker studies in general, I provide an overall assessment of the evidence regarding testing for CYP2D6 in making clinical decisions regarding the use of tamoxifen in ...
openaire   +2 more sources

CYP2D6 genetic variation in Ugandans

European Journal of Clinical Pharmacology, 2021
Jun Miura, Celestino Obua, Catherine Abbo, Tomonori Tateishi, Sunao Kaneko   +4 more
openaire   +2 more sources